Asset Details
Do you wish to reserve the book?
Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT
Do you wish to request the book?
Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT
2017
Overview
Purpose
In phase I/II-studies radiolabelled ABY-025 Affibody molecules identified human epidermal growth factor receptor 2 (HER2) expression in breast cancer metastases using PET and SPECT imaging. Here, we wanted to investigate the utility of a simple intra-image normalization using tumour-to-reference tissue-ratio (T/R) as a HER2 status discrimination strategy to overcome potential issues related to cross-calibration of scanning devices.
Methods
Twenty-three women with pre-diagnosed HER2-positive/negative metastasized breast cancer were scanned with [
111
In]-ABY-025 SPECT/CT (n = 7) or [
68
Ga]-ABY-025 PET/CT (n = 16). Uptake was measured in all metastases and in normal spleen, lung, liver, muscle, and blood pool. Normal tissue uptake variation and T/R-ratios were established for various time points and for two different doses of injected peptide from a total of 94 whole-body image acquisitions. Immunohistochemistry (IHC) was used to verify HER2 expression in 28 biopsied metastases. T/R-ratios were compared to IHC findings to establish the best reference tissue for each modality and each imaging time-point. The impact of shed HER2 in serum was investigated.
Results
Spleen was the best reference tissue across modalities, followed by blood pool and lung. Spleen-T/R was highly correlated to PET SUV in metastases after 2 h (r = 0.96, P < 0.001) and reached an accuracy of 100% for discriminating IHC HER2-positive and negative metastases at 4 h (PET) and 24 h (SPECT) after injection. In a single case, shed HER2 resulted in intense tracer retention in blood. In the remaining patients shed HER2 was elevated, but without significant impact on ABY-025 biodistribution.
Conclusion
T/R-ratios using spleen as reference tissue accurately quantify HER2 expression with radiolabelled ABY-025 imaging in breast cancer metastases with SPECT and PET. Tracer binding to shed HER2 in serum might affect quantification in the extreme case.
Publisher
Springer Berlin Heidelberg,Springer Nature B.V
Subject
/ Affibody
/ Aged
/ Binding
/ Blood
/ Breast Neoplasms - diagnostic imaging
/ Breast Neoplasms - metabolism
/ Breast Neoplasms - pathology
/ Cancer
/ Devices
/ Gene Expression Regulation, Neoplastic
/ Humans
/ Imaging
/ Liver
/ Lungs
/ Medicine
/ Oncology
/ Original
/ Patients
/ Peptide Fragments - pharmacokinetics
/ PET
/ Positron Emission Tomography Computed Tomography
/ Receptor, ErbB-2 - metabolism
/ Scanning
/ Shedding
/ Single photon emission computed tomography
/ SPECT
/ Spleen
/ T/R
/ Tomography, Emission-Computed, Single-Photon
/ Tumors
